ATLANTA -- (Business Wire)
Holzer & Holzer, LLC is investigating whether Evolus, Inc. (“Evolus” or
the “Company”) (NASDAQ: EOLS) complied with the federal securities laws.
On May 16, 2018, Evolus announced that the FDA sent a Complete Response
Letter related to the Company’s Biologics License Application for
DWP-450, a developmental treatment of frown lines. The FDA’s Complete
Response Letter noted deficiencies in Evolus’ Chemistry, Manufacturing
and Controls processes. The price of Evolus stock fell following the
If you purchased Evolus common stock and suffered a loss on that
investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com
or Alexandria P. Rankin, Esq. at firstname.lastname@example.org,
or call the firm by toll-free telephone at (888) 508-6832.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its
practice to vigorous representation of shareholders and investors in
litigation nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its
and upon request from the firm. Holzer & Holzer, LLC has paid for the
dissemination of this promotional communication, and Corey D. Holzer is
the attorney responsible for its content.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516006157/en/
Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832
Source: Holzer & Holzer, LLC
© 2018 Canjex Publishing Ltd. All rights reserved.